ClinicalTrials.gg
RecruitingNCT05539391OSETIMUpdated Nov 13, 2026

Optimisation Strategy for Emergency Tracheal Intubation

An interventional study of Data patient and Physical examination in Emergencies, Out-of-hospital Setting and Tracheal Intubation, sponsored by University Hospital, Bordeaux. Recruiting at 22 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionnone(registry's first term: Emergencies)No conditionIs this wrong?Emergencies describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study has to objective to assess, in adults' patients needing tracheal intubation because of vital distress, the effect of a combined strategy to reduce intubation-related morbidity. This strategy will associate systematic use of rocuronium as paralyzing agent to facilitate tracheal intubation, bag face-mask ventilation before intubation and Gum Elastic Bougie (GEB) use.

Read the detailed description

Several studies have reported positive impact of some interventions on the tracheal intubation-related complications incidence. Providing bag face-mask ventilation between medication administration and initiation of laryngoscopy significantly reduced the number of peri intubation hypoxemia episodes. The use of a non-depolarizing (rocuronium) paralytic agent instead of succinylcholine is associated with less post-intubation complications occurrence. Finally, use of a tracheal tube introducer (GEB) as an aid for intubation in emergency patients with at least one prognostic factor of difficult laryngoscopy has been shown to facilitate intubation. Assessment of a strategy combining these three interventions to reduce intubation related morbidity in emergency situations has never been assessed. It is expected that the combination of these interventions will drastically reduce the morbidity associated with emergency intubation. The strategy assessed will associate rocuronium use as paralyzing agent to facilitate intubation, bag mask ventilation before intubation and GEB use at first intubation attempt in all patients. The emergency physician in charge of the patients will record out-of hospital outcomes immediately after the out-of-hospital period. Intra-hospital data will be retrieved from the patient's medical record on the 28th day after inclusion.

02

Conditions studied

  • Emergencies
  • Out-of-hospital Setting
  • Tracheal Intubation

Browse trials for

Keywords

  • Out-of-hospital
  • Intubation
  • Complications
  • Vital distress
  • Rapid sequence intubation
  • Rocuronium
  • Gum Elastic Bougie
03

In context

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient adult (≥ 18 years) presenting with vital distress requiring emergency tracheal intubation as assessed by the emergency physician in the out-of-hospital setting.
  • Patient with all conditions (trauma, dyspnea, coma, overdoses, and shock) except those in cardiac arrest will be included.

Exclusion criteria

Exclusion Criteria:

  • Patient presenting of a to succinylcholine, and/or rocuronium, and/or sugammadex (rocunorium antagonist).
  • Patient who have contraindication to bag face mask ventilation before intubation (ongoing emesis, hematemesis, or hemoptysis).
  • Patient that are not members of a medical aid scheme (beneficiary or main member).
  • Patient under specific protection measures: pregnant, parturient or nursing women; legal protection or deprived of liberty: patient under judicial protection, patient under guardianship/curatorship.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Combination rapid sequence intubation (RSI) with use of rocuronium and the bag-mask ventilation between induction and Gum Elastic Bougie GEB will be systematically used at the first attempt to facilitate intubation.

    Other: Data patient · Other: Physical examination · Procedure: Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB

  • Active comparator
    Control Group

    Physicians will be reminded of the current recommendations for emergency intubation: Rapid sequence intubation (RSI) using succinylcholine and use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.

    Other: Data patient · Other: Physical examination · Procedure: Rapid sequence intubation (RSI) : Recommendations for emergency intubation

Interventions

  • OtherData patient

    Medical History and characteristic of patient

  • OtherPhysical examination

    Arterial pressure, arterial oxygen saturation, heart rate

  • ProcedureRapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB

    Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.

  • ProcedureRapid sequence intubation (RSI) : Recommendations for emergency intubation

    Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.

06

What researchers measure

Primary outcomes

  1. Severe intubation-related complications occurring during the first hour after intubation

    Proportion of patients with severe intubation-related complications occurring during the first hour after intubation The severe intubation-related complications are: * Cardiac arrest. * At least one arterial hypotension episode defined by systolic blood pressure\<90 mmHg. * At least one hypoxemia episode defined by an occurrence of a new episode of oxygen. * Saturation \< 90%. * Severe cardiac arrhythmia: ventricular tachycardia. * Pulmonary aspiration, reported by the physician. * Esophageal intubation. * Unintentional extubation. Severe intubation-related complications will be recorded by the emergency physician in charge of the patient.

    Time frame: Day 0

Secondary outcomes

  1. Difficulty of the intubation process - Intubation Difficulty

    Intubation Difficulty Score (IDS). minimum values is 0 and the maximum values is dependent on the added elements.

    Time frame: Day 0

  2. Difficulty of the intubation process - Intubation conditions assessed by the Copenhagen

    Intubation conditions assessed by the Copenhagen score - The value is clinically not acceptable and clinical acceptable

    Time frame: Day 0

  3. Difficulty of the intubation process - Alternative techniques.

    Proportion of patients intubated by alternative techniques.

    Time frame: Day 0

  4. Difficulty of the intubation process - Intubation attempts

    Mean number of intubation attempts

    Time frame: Day 0

  5. Difficulty of the intubation process - Intubation failures under direct laryngoscopy.

    Mean number of intubation failures under direct laryngoscopy.

    Time frame: Day 0

  6. Out-of hospital care -Time of out-of-hospital care

    Mean time of out-of-hospital care (in minutes)

    Time frame: Day 0

  7. Out-of hospital care - sedative drugs

    Mean total amount of sedative drugs used after intubation

    Time frame: Day 0

  8. Out-of hospital care - vasopressors

    Mean total amount of vasopressors used after intubation

    Time frame: Day 0

  9. Out-of hospital care : Mortality

    Out-of-hospital mortality.

    Time frame: Day 0

  10. Mortality

    Vital status

    Time frame: Day 28

07

Study locations

19 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2023 (actual). Primary completion is estimated for Sep 2027, 56 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2022
First posted
Sep 14, 2022
StartActual
Jan 14, 2023
Primary completionEst.
Sep 14, 2027was Sep 2026
CompletionEst.
Sep 14, 2027was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 14, 2027
Nov 13, 2026
Study completion
Sep 2026→Sep 14, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Sep 2026→Sep 14, 2027
    Study completion Sep 2026→Sep 14, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05539391
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
Jan 14, 2023
Primary completion
Sep 14, 2027 (estimated)
Completion
Sep 14, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Xavier COMBES, Pr
Contact
xavier.combes@chu-bordeaux.fr
05 56 79 49 47 ext. 033
Xavier COMBES, Pr
principal investigator · Université Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion